



International Journal of Biological & Pharmaceutical Research

e- ISSN 0976 - 3651
Print ISSN 2229 - 7480

www.ijbpr.com

Review Article

NEWER APPLICATIONS OF 2,4,6-TRISUBSTITUTED PYRIMIDINES AS POTENTIAL CYTOTOXIC AGENTS

Gaddam Vijaya Bhaskar Rao^{1*}, Zaheda Banu¹ and Hari Jagannadha Rao G²

^{1*}Guntur Medical College, Guntur, Andhra Pradesh, India.

²Ashran Medical College, Eluru, Andhra Pradesh, India.

ABSTRACT

A number of 2,4,6-trisubstituted pyrimidines were reported to possess diverse biological activities like antimicrobial, antidepressant, analgesic, anti-inflammatory, anticancer, antiviral, antileishmanial, antituberculosis, anti-HIV and antimalarial activities. In view of the varied biological and pharmacological importance of pyrimidine derivatives, it is felt worthwhile to evaluate them for possible activities. These compounds therefore were screened for anticancer activity the IC-50 values of synthesized compounds revealed that the compounds having dihalogen substitution (B₆P₆ and B₅P₅) were found to be more potent than the compounds having electron releasing substituents. Pyrimidines with monohalogen substitution also enhanced the anticancer activity. Among all the compounds, compounds with fluorine substitution significantly enhanced the activity followed by compounds with chloro substitution.

Key Words: Pyrimidines, Cytotoxic etc.

Access this article online

Home page: <http://ijbpr.com/>

DOI:

<http://dx.doi.org/10.21276/ijbpr.2017.8.1.2>

Quick Response
code



Received:25.10.16

Revised:12.11.16

Accepted:15.11.16

Corresponding Author

Gaddam Vijaya Bhaskar rao

Guntur Medical College, Guntur, Andhra Pradesh,
India.

Email:- vijay057pharma@yahoo.co.in

INTRODUCTION

Pyrimidine is a six-membered heterocycle with two nitrogen atoms situated in a 1,3-arrangement. It is also known as *m*-diazine or 1,3-diazine. Both nitrogen atoms are like the pyridine


nitrogen (Maayan S *et al.*, 2005; Nowakowska N, 2007; Go ML *et al.*, 2005). A number of 2,4,6-trisubstituted pyrimidines were reported to possess diverse biological activities like antimicrobial, antidepressant, analgesic, anti-inflammatory, anticancer, antiviral, antileishmanial, antituberculosis, anti-HIV and antimalarial activities (Elizabeth P *et al.*, 2006). In view of the varied biological and pharmacological importance of pyrimidine derivatives, it is felt worthwhile to evaluate them for possible activities. These compounds therefore were screened for anticancer activity (Tsukiyama RI *et al.*, 2002; Machodo TB *et al.*, 2005; Rao NR *et al.*, 2004).

MATERIALS AND METHODS

General procedure for the synthesis of 2,4,6-trisubstituted pyrimidines
Synthesis of 2-amino-4-(2'-furyl)-6-(3",4",5"-trimethoxyphenyl) pyrimidine (b₁p₁)

1-(2 -furyl)-3-(3",4",5"-trimethoxyphenyl)-2-pro pen-1-one (B₁) (0.001 mol) was condensed with

guanidine hydrochloride (0.001 mol) in the presence of potassium hydroxide (0.002 mol) in absolute ethanol (5 ml) at reflux temperature on a water bath for 3 hrs. The solvent was evaporated *in vacuo* and crushed ice was added to the residue while mixing thoroughly, whereupon a bright yellow solid separated out. This solid was filtered under vacuum, dried and purified by column chromatography to give pure pale yellow solid. Physical characterization data of 2,4,6-trisubstituted pyrimidines were given in table-1, spectral data were given in table-2 and 3



BIOLOGICAL EVALUATION

Anticancer activity

Methodology

The synthesized pyrimidines have been screened for anticancer activity on prostate cancer cell lines (DU-145) using MTT based cytotoxicity assay.

Chemicals/Biochemicals used in the present study

- Media: DMEM (Dulbecco's Modified Eagles Medium)
- 10 % Fetal bovine serum (FBS)
- MTT reagent : [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
- Cell lines: DU-145 cell lines, were obtained from the National Centre for Cell Science (NCCS), pune (India)

Procedure

This method is based on a colorimetric assay which takes into account the ability of a mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale yellow MTT and form dark blue formazan crystals which is largely impermeable to cell membranes, thus resulting in its accumulation within healthy

cells. The level of formazan created is a reflection of the number of surviving cells and shows a proportionality relationship between them.

The required cell proliferation assay kit was obtained from Roche Applied Sciences, Germany. The procedure consists of seeding an equal number of DU-145 cells in each well of a 96-well microplate and incubating at 37°C in the presence of 5 % CO₂. Various concentrations of the test substances were added to the cells. For every 24 hrs the culture medium was renewed with the test substances. 0.5 % DMSO was added into the vehicle control culture wells. After 72 hrs treatment, 5 µl of MTT reagent (R&D systems USA) along with 45 µl of phenol red and FBS free DMEM (Sigma Life Science, USA) was added to each well and incubated for 4 hrs at 37°C in presence of 5 % CO₂. Then 50 µl of solubilization buffer (R&D systems, USA) was added to each well to solubilize the coloured formazan crystals produced by the reduction of MTT. After 24 hrs the optical density was measured at 550 nm using a microplate reader (BioRad, USA). The results (mean O.D. ± SD) obtained from quadruplicate wells were used in calculation to determine the IC₅₀ of the test compounds.

The percent inhibition is then calculated from the formula:


$$\% \text{ inhibition} = \frac{\text{Control O.D.} - \text{Sample O.D.}}{\text{Control O.D.}} \times 100$$

The dose levels of those pyrimidines which showed a minimum of 50 % inhibition (IC₅₀) were shown in table-4

RESULTS AND DISCUSSION

The IC-50 values for pyrimidines revealed that the compounds having dihalogen substitution (B₆P₆ and B₅P₅) were found to be more potent than the compounds having electron releasing substituents. Pyrimidines with monohalogen substitution also enhanced the anticancer activity. Among all the compounds, compounds with fluorine substitution significantly enhanced the activity followed by compounds with chloro substitution.

Table 1. Physical characterization data of 2,4,6-trisubstituted pyrimidines(B₁P₁-B₁₀P₁₀)











Compound	Structure	Molecular Formula	Relative Molecular Mass(RMM)	Melting Point (°C)	Yield %
B ₁ P ₁		C ₁₇ H ₁₇ N ₃ O ₄	327	315-319	52
B ₂ P ₂		C ₁₄ H ₁₀ ClN ₃ O ₂	271	250-254	64
B ₃ P ₃		C ₁₆ H ₁₆ N ₄ O	280	178-182	59
B ₄ P ₄		C ₁₅ H ₁₃ N ₃ O	251	148-150	45
B ₅ P ₅		C ₁₄ H ₉ Cl ₂ N ₃ O	325	143-147	57
B ₆ P ₆		C ₂₂ H ₁₅ N ₃ O	337	238-240	71
B ₇ P ₇		C ₁₅ H ₁₃ N ₃ O ₂	267	313-317	62
B ₈ P ₈		C ₁₆ H ₁₅ N ₃ O ₃	297	223-225	67
B ₉ P ₉		C ₁₄ H ₁₀ FN ₃ O	255	241-243	43
B ₁₀ P ₁₀		C ₁₄ H ₁₀ N ₄ O ₃	282	264-268	53

Table 2. IR spectral data (KBr disc) of 2,4,6-trisubstituted pyrimidines (B₁P₁-B₁₀P₁₀)

Compound	Position of absorption band (cm ⁻¹)
B ₁ P ₁	3414, 3380 (NH ₂), 1591 (C=N), 1503 (C=C), 1387(C-N),1228 (C-O-C), 1178 (O-CH ₃)
B ₂ P ₂	3405, 3346 (NH ₂), 1636 (C=N), 1578 (C=C),1383 (C-N), 858 (C-Cl)
B ₃ P ₃	3410, 3332 (NH ₂), 1610 (C=N), 1570 (C=C), 1391 (C-N),1178 (-N (CH ₃) ₂)
B ₄ P ₄	3412, 3335 (NH ₂), 1597 (C=N), 1520 (C=C), 1365 (C-N)
B ₅ P ₅	,3410, 3326 (NH ₂), 1605 (C=N), 1525 (C=C),1372 (C-N),892 (C-Cl)
B ₆ P ₆	3413, 3328 (NH ₂), 1632 (C=N), 1515 (C=C), 1375 (C-N)
B ₇ P ₇	3414 (NH ₂), 1598 (C=N), 1503 (C=C), 1366 (C-N),1225 (C-O-C)
B ₈ P ₈	3320, 3187 (NH ₂), 1597 (C=N), 1556 (C=C), 1354 (C-N), 1261(C-O-C)

B ₉ P ₉	3468, 3318(NH ₂), 1599 (C=N), 1510 (C=C), 1350(C-N), 1219 (C-F)
B ₁₀ P ₁₀	3370 (NH ₂), 1645 (C=N), 1557 (N=O, asymmetric), 1406 (C-N),1350 (N=O, symmetric)

Table 3. ¹H NMR spectral data (400MHz) of 2,4,6-trisubstituted pyrimidines (B₁P₁ – B₁₀P₁₀)

Compound	Chemical shift (δ) in ppm
B ₁ P ₁	3.75-4.0 (9H, s, 3xOCH ₃), 5.15 (2H, s, -NH ₂), 6.45-6.60 (1H, m, C-4'-H) 7.38 (1H, d, J=6.0Hz, C-5'-H), 7.0 (1H, S ,C-5-H) 6.40 (2H, S , C-2''-H and C-6''-H), 7.28 (1H, d, J=6.0Hz C-3'-H)
B ₂ P ₂	5.45 (2H, s, -NH ₂), 6.60 (1H, m , C-4'-H),8.03 (2H, d , J=8.0Hz, C-3''-H and C-5''-H),7.48 (2H, d, J=8.0Hz, C-2''-H and C-6''-H),7.62 (1H, d, J=6.5Hz and C-5'-H) 7.30 (1H, d, J=6.5Hz and C-3'-H), 7.40 (1H, S, C-5-H)
B ₃ P ₃	3.10 (6H, s, -N(CH ₃) ₂), 5.20 (1H, s , -NH ₂), 6.61 (1H, m , C-4'-H), 7.36 (1H, s , C-5-H),8.12 (2H, d , J=8.5Hz, C-3''-H and C-5''-H),6.78 (2H, d , J=8.5Hz, C-2''-H and C-6''-H),7.67 (2H, d, J=6.0Hz, C-3'-H and C-5'-H)
B ₄ P ₄	2.46 (3H, s, Ar-CH ₃), 5.25 (2H, s, -NH ₂), 6.67 (1H, m, C-4'-H), 7.45 (1H, s, C-5-H), 8.06 (2H, d, J=8.0Hz, C-3''-H and C-5''-H), 7.36 (2H, d, J=8.0Hz, C-2''-H and C-6''-H), 7.71(1H, d, J=6.0Hz, C-5'),7.60 (1H, d, J=6.0Hz, C-3'H)
B ₅ P ₅	5.78 (2H, s, -NH ₂), 6.62 (1H, m, C-4'-H),7.62 (1H, s , -C-3''-H),7.64 (1H, d, J=6.5Hz, C-5'-H), 7.54 (1H, d, J=8.5Hz, C-5''-H),7.41 (1H, d, J=8.5Hz, C-6''-H), 7.39 (1H, d, J=6.5Hz, C-3'-H),7.35 (1H, s, C-5-H)
B ₆ P ₆	5.85 (2H,s, -NH ₂), 6.61 (1H,m, C-4'-H), 7.60 (1H,s, C-5-H) 8.06 (1H, d, J=6.0Hz, C-5'-H), 7.78 (1H, d, J=6.0Hz, C-3'-H) 7.22-7.55(9H, m, Ar-H)
B ₇ P ₇	3.87 (3H, s, C-4''-OCH ₃), 5.11 (2H, s, C-2-NH ₂), 6.56 (2H, d, J=6.0 Hz, C-3' and 5'-H), 7.07 (2H, d, J=8.5 Hz, C-3''and 5''-H), 7.37 (1H, s, C-5-H), 7.58 (1H, s, C-2'-H), 8.05 (2H, d, J=8.5 Hz, C-2'' and 6''-H)
B ₈ P ₈	5.63 (2H, s, C-4'-NH ₂), 5.21 (2H, s, C-2-NH ₂), 6.64 (2H, d, J=6.5 Hz, C-3'), 7.19 (2H, dd, J=8.5 Hz, C-2'' and 6''-H), 7.37 (1H, s, C-5-H),8.084 (2H, dd, J=8.5 Hz, J=8.5 Hz, C-3'' and 5''-H)
B ₉ P ₉	5.63 (2H, s, C-4'-NH ₂), 5.21 (2H, s, C-2-NH ₂), 6.64 (2H, d, J=6.5 Hz, C-3'), 7.19 (2H, dd, J=8.5 Hz, C-2'' and 6''-H), 7.37 (1H, s, C-5-H), 8.084 (2H, dd, J=8.5 Hz, J=8.5 Hz, C-3'' and 5''-H)
B ₁₀ P ₁₀	5.22 (1H, s, C-2-NH ₂), 6.64-6.65 (1H, t, C-4'-H),7.62-7.58 (2H, m, C-3'), 7.79 (2H, d, J=8.0Hz, C-2'' and 6''-H),7.88 (1H, d ,J=16Hz, -CO-CH=),8.24 (1H, d, J=15.6Hz, Ar-CH=),8.34 (2H, d, J=8.0Hz, C-3''and 5''-H)

Table 4. Anticancer Activity of trisubstituted pyrimidines (B₁P₁-B₁₀P₁₀), by MTT Assay on Human Prostate Cancer Cell Lines (DU-145)

Compounds	Ar	IC ₅₀ (μ g/ml)
B ₁ P ₁	4-methylphenyl	115
B ₂ P ₁	4-fluorophenyl	24
B ₃ P ₃	4-chlorophenyl	36
B ₄ P ₄	2-chlorophenyl	59
B ₅ P ₅	2,4-difluorophenyl	22
B ₆ P ₆	2,4-dichlorophenyl	27
B ₇ P ₇	3-nitrophenyl	86
B ₈ P ₈	3,4,5-trimethoxyphenyl	120
B ₉ P ₉	3-nitro-4-methylphenyl	92
B ₁₀ P ₁₀	5-bromofuryl	39

CONCLUSION

The above IC-50 values for pyrimidines revealed that the compounds having dihalogen substitution (B₆P₆ and B₅P₅) were found to be more potent than the compounds having electron releasing

substituents. Pyrimidines with monohalogen substitution also enhanced the anticancer activity. Among all the compounds, compounds with fluorine substitution significantly enhanced the activity followed by compounds with chloro substitution.

Pyrimidines having number of either of these substituents or both these substituents at different positions of the phenyl ring can be synthesized as the resulting compounds are likely to possess significant activity.

ACKNOWLEDGEMENT: None

CONFLICT OF INTEREST:

The authors declare that they have no conflict of interest.

REFERENCES

- Elizabeth P, Rosa MM, Casal B, Carlos J, Willma N, Zhang XF and Yeung KL. Anti pyrimidines as inflammatory agents. *Catalysis Today*. 2006; 96.
- Go ML, Wu X and Li XL. Pyrimidine the molecule of diverse and biological importance. *Current Medicinal Chemistry*. 2005; 12: 483.
- Maayan S, Ohad N and Soliman K. Synthesis and reactions of new pyrimidine derivatives as anticonvulsant agents. *Bioorg. Med. Chem*. 2005; 13: 433.
- Machodo TB, Leal ICR, Kuster RM, Amaral ACF and Santos KRN. Clinical use of systemic anti fungal agents. *Phytother. Res*. 2005; 19: 519.
- Nowakowska N. Synthesis and antimicrobial evaluation of iodopyrimidine derivative. *Eur. J. Med. Chem*. 2007; 42: 125.
- Rao NR, Rao GS and Mukkanti P. *The Pharma Review*. 2004; 117.
- Tsukiyama RI, Katsura H, Tokuriki N and Kobayashi M. Newer applications of pyrimidine derivatives *Antimicrobial Agents Chemother*. 2002; 46: 1226.

Cite this article:

Gaddam Vijaya Bhaskar Rao, Zaheda Banu and Hari Jagannadha Rao G. Newer Applications of 2,4,6-Trisubstituted Pyrimidines as Potential Cytotoxic Agents. *International Journal of Biological & Pharmaceutical Research*. 2017; 8(1):5-9. DOI: <http://dx.doi.org/10.21276/ijbpr.2017.8.1.2>



[Attribution-NonCommercial-NoDerivatives 4.0 International](https://creativecommons.org/licenses/by-nc-nd/4.0/)